ESTA
Establishment Labs Holdings Inc.
Medical - Devices
Market Cap$2.12B
5Y Perf.+266.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ESTA vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1712.35T
5Y Perf.-58.8%
ESTA vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ESTA | DBVT |
|---|---|---|
| Industry | Medical - Devices | Biotechnology |
| Market Cap | $2.12B | $1712.35T |
| Revenue (TTM) | $211M | $0.00 |
| Net Income (TTM) | $-51M | $-168M |
| Gross Margin | 69.3% | — |
| Operating Margin | -18.5% | — |
| Total Debt | $264M | $22M |
| Cash & Equiv. | $76M | $194M |
ESTA vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ESTA
DBVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Establishment Labs … (ESTA) | 100 | 366.0 | +266.0% |
| DBV Technologies S.… (DBVT) | 100 | 41.2 | -58.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ESTA vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ESTA leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. DBV Technologies S.A. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
ESTA
Establishment Labs Holdings Inc.
The Growth Play
ESTA carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 27.1%, EPS growth 42.7%, 3Y rev CAGR 9.3%
- 191.0% 10Y total return vs DBVT's -87.0%
- 27.1% revenue growth vs DBVT's -100.0%
Best for: growth exposure and long-term compounding
DBVT
DBV Technologies S.A.
The Income Pick
DBVT is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 0 yrs, beta 1.26
- Lower volatility, beta 1.26, Low D/E 12.8%, current ratio 3.67x
- Beta 1.26, current ratio 3.67x
Best for: income & stability and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ESTA | 27.1% revenue growth vs DBVT's -100.0% |
| Quality / Margins | DBVT | 0.3% margin vs ESTA's -24.2% |
| Stability / Safety | DBVT | Beta 1.26 vs ESTA's 1.30, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ESTA | +116.5% vs DBVT's +110.4% |
| Efficiency (ROA) | ESTA | -15.0% ROA vs DBVT's -89.0% |
ESTA vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLESTALAGGINGDBVT
DBVTDBV Technologies S.A.
1leads
ESTAEstablishment Labs Ho…
1leads
6 Total Categories
CATEGORYLEADERvs DBVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ESTA1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
DBVT4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ESTA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ESTA and DBVT operate at a comparable scale, with $211M and $0 in trailing revenue.
| Metric | ESTAEstablishment Lab… | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $211M | $0 |
| EBITDAEarnings before interest/tax | -$32M | -$112M |
| Net IncomeAfter-tax profit | -$51M | -$168M |
| Free Cash FlowCash after capex | -$57M | -$151M |
| Gross MarginGross profit ÷ Revenue | +69.3% | — |
| Operating MarginEBIT ÷ Revenue | -18.5% | — |
| Net MarginNet income ÷ Revenue | -24.2% | — |
| FCF MarginFCF ÷ Revenue | -27.2% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +45.2% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +92.6% | +91.5% |
ESTA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — ESTA and DBVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ESTAEstablishment Lab… | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $2.1B | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $2.3B | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | -41.88x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 10.03x | — |
| Price / BookPrice ÷ Book value/share | 90.61x | 0.66x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — ESTA and DBVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
DBVT leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
DBVT delivers a -130.2% return on equity — every $100 of shareholder capital generates $-130 in annual profit, vs $-2 for ESTA. DBVT carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to ESTA's 11.23x.
| Metric | ESTAEstablishment Lab… | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | -2.0% | -130.2% |
| ROA (TTM)Return on assets | -15.0% | -89.0% |
| ROICReturn on invested capital | -14.6% | — |
| ROCEReturn on capital employed | -14.1% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 |
| Debt / EquityFinancial leverage | 11.23x | 0.13x |
| Net DebtTotal debt minus cash | $189M | -$172M |
| Cash & Equiv.Liquid assets | $76M | $194M |
| Total DebtShort + long-term debt | $264M | $22M |
| Interest CoverageEBIT ÷ Interest expense | -1.30x | -189.82x |
DBVT leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — ESTA and DBVT each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ESTA five years ago would be worth $10,061 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, ESTA leads with a +116.5% total return vs DBVT's +110.4%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs ESTA's 2.1% — a key indicator of consistent wealth creation.
| Metric | ESTAEstablishment Lab… | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | +4.6% | +4.9% |
| 1-Year ReturnPast 12 months | +116.5% | +110.4% |
| 3-Year ReturnCumulative with dividends | +6.4% | +19.7% |
| 5-Year ReturnCumulative with dividends | +0.6% | -69.1% |
| 10-Year ReturnCumulative with dividends | +191.0% | -87.0% |
| CAGR (3Y)Annualised 3-year return | +2.1% | +6.2% |
Evenly matched — ESTA and DBVT each lead in 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ESTA and DBVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
DBVT is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than ESTA's 1.30 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ESTA currently trades 86.5% from its 52-week high vs DBVT's 76.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ESTAEstablishment Lab… | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.30x | 1.26x |
| 52-Week HighHighest price in past year | $83.31 | $26.18 |
| 52-Week LowLowest price in past year | $32.75 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +86.5% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 66.8 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 455K | 252K |
Evenly matched — ESTA and DBVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ESTA as "Buy" and DBVT as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 18.0% for ESTA (target: $85).
| Metric | ESTAEstablishment Lab… | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $85.00 | $46.33 |
| # AnalystsCovering analysts | 14 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ESTA leads in 1 of 6 categories (Income & Cash Flow). DBVT leads in 1 (Profitability & Efficiency). 3 tied.
Best OverallEstablishment Labs Holdings… (ESTA)Leads 1 of 6 categories
Loading custom metrics...
ESTA vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ESTA or DBVT a better buy right now?
Analysts rate Establishment Labs Holdings Inc.
(ESTA) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ESTA or DBVT?
Over the past 5 years, Establishment Labs Holdings Inc.
(ESTA) delivered a total return of +0. 6%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: ESTA returned +191. 0% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ESTA or DBVT?
By beta (market sensitivity over 5 years), DBV Technologies S.
A. (DBVT) is the lower-risk stock at 1. 26β versus Establishment Labs Holdings Inc. 's 1. 30β — meaning ESTA is approximately 4% more volatile than DBVT relative to the S&P 500. On balance sheet safety, DBV Technologies S. A. (DBVT) carries a lower debt/equity ratio of 13% versus 11% for Establishment Labs Holdings Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — ESTA or DBVT?
On earnings-per-share growth, the picture is similar: Establishment Labs Holdings Inc.
grew EPS 42. 7% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ESTA or DBVT?
DBV Technologies S.
A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -24. 2% for Establishment Labs Holdings Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -18. 5% for ESTA. At the gross margin level — before operating expenses — ESTA leads at 69. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ESTA or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ESTA or DBVT better for a retirement portfolio?
For long-horizon retirement investors, Establishment Labs Holdings Inc.
(ESTA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+191. 0% 10Y return). Both have compounded well over 10 years (ESTA: +191. 0%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ESTA and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ESTA is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.